Nature Communications (Sep 2021)
Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential
- Bjoern Meyer,
- Jeanne Chiaravalli,
- Stacy Gellenoncourt,
- Philip Brownridge,
- Dominic P. Bryne,
- Leonard A. Daly,
- Arturas Grauslys,
- Marius Walter,
- Fabrice Agou,
- Lisa A. Chakrabarti,
- Charles S. Craik,
- Claire E. Eyers,
- Patrick A. Eyers,
- Yann Gambin,
- Andrew R. Jones,
- Emma Sierecki,
- Eric Verdin,
- Marco Vignuzzi,
- Edward Emmott
Affiliations
- Bjoern Meyer
- Viral Populations and Pathogenesis Unit, CNRS, UMR 3569, Institut Pasteur
- Jeanne Chiaravalli
- Chemogenomic and Biological Screening Core Facility, C2RT, Departments of Cell Biology & Infection and of Structural Biology & Chemistry, Institut Pasteur
- Stacy Gellenoncourt
- CIVIC Group, Virus & Immunity Unit, Institut Pasteur and CNRS
- Philip Brownridge
- Centre for Proteome Research, Department of Biochemistry & Systems Biology, Institute of Systems, Molecular & Integrative Biology, Biosciences Building, Crown Street, University of Liverpool
- Dominic P. Bryne
- Department of Biochemistry & Systems Biology, Institute of Systems, Molecular & Integrative Biology, Biosciences Building, Crown Street, University of Liverpool
- Leonard A. Daly
- Centre for Proteome Research, Department of Biochemistry & Systems Biology, Institute of Systems, Molecular & Integrative Biology, Biosciences Building, Crown Street, University of Liverpool
- Arturas Grauslys
- Computational Biology Facility, LIV-SRF, Institute of Systems, Molecular & Integrative Biology, Biosciences Building, Crown Street, University of Liverpool
- Marius Walter
- Buck Institute for Research on Aging
- Fabrice Agou
- Chemogenomic and Biological Screening Core Facility, C2RT, Departments of Cell Biology & Infection and of Structural Biology & Chemistry, Institut Pasteur
- Lisa A. Chakrabarti
- CIVIC Group, Virus & Immunity Unit, Institut Pasteur and CNRS
- Charles S. Craik
- Department of Pharmaceutical Chemistry, University of California, San Francisco
- Claire E. Eyers
- Centre for Proteome Research, Department of Biochemistry & Systems Biology, Institute of Systems, Molecular & Integrative Biology, Biosciences Building, Crown Street, University of Liverpool
- Patrick A. Eyers
- Department of Biochemistry & Systems Biology, Institute of Systems, Molecular & Integrative Biology, Biosciences Building, Crown Street, University of Liverpool
- Yann Gambin
- EMBL Australia Node for Single Molecule Sciences, and School of Medical Sciences, Botany Road, The University of New South Wales
- Andrew R. Jones
- Department of Biochemistry & Systems Biology, Institute of Systems, Molecular & Integrative Biology, Biosciences Building, Crown Street, University of Liverpool
- Emma Sierecki
- EMBL Australia Node for Single Molecule Sciences, and School of Medical Sciences, Botany Road, The University of New South Wales
- Eric Verdin
- Buck Institute for Research on Aging
- Marco Vignuzzi
- Viral Populations and Pathogenesis Unit, CNRS, UMR 3569, Institut Pasteur
- Edward Emmott
- Centre for Proteome Research, Department of Biochemistry & Systems Biology, Institute of Systems, Molecular & Integrative Biology, Biosciences Building, Crown Street, University of Liverpool
- DOI
- https://doi.org/10.1038/s41467-021-25796-w
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 16
Abstract
During SARS-CoV-2 replication, viral and cellular proteases play crucial roles and have been shown to be promising anti-viral targets. Here, Meyer et al. apply mass spectrometry to characterize the proteolytic cleavage profile of viral and cellular proteins in vitro.
